Plasma levels of soluble interleukin 1 receptor accessory protein are reduced in obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3435-3443

  Bozaoglu, Kiymet ^a   Attard, Chantal ^a   Kulkarni, Hemant ^b   Cummings, Nik ^a   Diego, Vincent P ^b   Carless, Melanie A ^b   Shields, Katherine A ^a   Johnson, Matthew P ^b   Kowlessur, Sudhir ^c   Dyer, Thomas D ^b   Comuzzie, Anthony G ^b   Almasy, Laura ^b   Zimmet, Paul ^a   Moses, Eric K ^b   Göring, Harald H H ^b   Curran, Joanne E ^b   Blangero, John ^b   Jowett, Jeremy B M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c Ministry of Health and Quality of Life   (Mauritius)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; BIOLOGICAL MARKER; IL1RAP PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY ASSESSMENT; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HERITABILITY; HUMAN; IL1RAP GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MAURITIUS; OBESITY; PHENOTYPE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH ASIAN; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MEXICAN AMERICAN; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SOLUBILITY; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATION; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; MALE; MAURITIUS; MEXICAN AMERICANS; MIDDLE AGED; MODELS, GENETIC; OBESITY; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SOLUBILITY; TEXAS; YOUNG ADULT;

EID: 84907221081     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4475     Document Type: Article

References (45)

1. Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost. 2013;109: 399-406.
2. Suganami T, Tanaka M, Ogawa, Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocr J. 2012;59: 849-857.
3. Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: The role of glucose, lipids and endotoxin. J Endocrinol. 2013;216: T1-T15.
4. Smorlesi A, Frontini A, Giordano A, Cinti S. The adipose organ: White-brown adipocyte plasticity and metabolic inflammation. Obes Rev. 2012;13(suppl 2): 83-96.
5. Murray KN, Buggey HF, Denes A, Allan SM. Systemic immune activation shapes stroke outcome. Mol Cell Neurosci. 2013;53: 14-25.
6. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 2009;42: 1331-1346.
7. Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflammation links excess fat to insulin resistance: The role of the interleukin-1 family. Immunol Rev. 2012;249: 239-252.
8. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: Role in type 2 diabetes. Clin Chim Acta. 2012;413: 1163-1170.
9. Humphreys NE, Grencis RK. IL-1-dependent, IL-1R1-independent resistance to gastrointestinal nematodes. Eur J Immunol. 2009;39: 1036-1045.
10. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007; 104: 18660-18665.
11. Kakkar R, Lee RT. The IL-33/ST2 pathway: Therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7: 827-840.
12. Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008; 42: 358-364.
13. Lu HL, Yang CY, Chen HC, Hung CS, Chiang YC, Ting LP.Anovel alternatively spliced interleukin-1 receptor accessory protein mIL- 1RAcP687. Mol Immunol. 2008;45: 1374-1384.
14. Libra M, Mangano K, Anzaldi M, et al. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep. 2006;15: 1305-1308.
15. Smeets RL, Joosten LA, Arntz OJ, et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. 2005;52: 2202-2211.
16. Smith DE, Hanna R, Della F, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003;18: 87-96.
17. MacCluer JW, Stern MP, Almasy L, et al. Genetics of atherosclerosis risk factors in Mexican Americans. Nutr Rev. 1999;57: S59-S65.
18. Mitchell BD, Kammerer CM, Blangero J, et al. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study. Circulation. 1996;94: 2159-2170.
19. MacCluer JW, Stern MP, Almasy L, et al. Genetics of atherosclerosis risk factors in Mexican Americans. Nutr Rev. 1999;57: S59-65.
20. Goring HH, Curran JE, Johnson MP, et al. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat Genet. 2007;39: 1208-1216.
21. Mitchell BD, Almasy LA, Rainwater DL, et al. Diabetes and hypertension in Mexican American families: Relation to cardiovascular risk. Am J Epidemiol. 1999;149: 1047-1056.
22. Magliano DJ, Soderberg S, Zimmet PZ, et al. Mortality, all-cause and cardiovascular disease, over 15 years in multiethnic Mauritius: Impact of diabetes and intermediate forms of glucose tolerance. Diabetes Care. 2010;33: 1983-1989.
23. Soderberg S, Zimmet P, Tuomilehto J, et al. Increasing prevalence of Type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabet Med. 2005;22: 61-68.
24. Soderberg S, Zimmet P, Tuomilehto J, et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med. 2004;256: 37-47.
25. Voruganti VS, Lopez-Alvarenga JC, Nath SD, et al. Genetics of variation in HOMA-IR and cardiovascular risk factors in Mexican- Americans. J Mol Med (Berl). 2008;86: 303-311.
26. Chan DF, Li AM, Chan MH, et al. Validation of prediction equations for estimating resting energy expenditure in obese Chinese children. Asia Pac J Clin Nutr. 2009;18: 251-256.
27. Mamtani MR, Kulkarni, HR. Predictive performance of anthropometric indexes of central obesity for the risk of type 2 diabetes. Arch Med Res. 2005;36: 581-589.
28. Guerrero-Romero F, Rodriguez-Moran, M. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. Arch Med Res. 2003;34: 428-432.
29. Cummings N, Shields KA, Curran JE, et al. Genetic variation in SH3-domain GRB2-like (endophilin)-interacting protein 1 has a major impact on fat mass. Int J Obes (Lond). 2012;36: 201-206.
30. Duggirala R, Stern MP, Mitchell BD, et al. Quantitative variation in obesity-related traits and insulin precursors linked to the OB gene region on human chromosome 7. Am J Hum Genet. 1996;59: 694-703.
31. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148: 4687-4694.
32. Comuzzie AG, Hixson JE, Almasy L, et al.Amajor quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. Nat Genet. 1997;15: 273-276.
33. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62: 1198-1211.
34. Suo C, Toulopoulou T, Bramon E, et al Analysis of multiple phenotypes in genome-wide genetic mapping studies. BMC Bioinformatics. 2013;14: 151.
35. Burdick JT, ChenWM,Abecasis GR, Cheung, VG. In silico method for inferring genotypes in pedigrees. Nat Genet. 2006;38: 1002-1004.
36. Boerwinkle E, Chakraborty R, Sing, CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. I. Models and analytical methods. Ann Hum Genet. 1986;50: 181-194.
37. Blangero J, Goring HH, Kent JW Jr, et al. Quantitative trait nucleotide analysis using Bayesian model selection. Hum Biol. 2005;77: 541-559.
38. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb). 2005;95: 221-227.
39. Barrett JC, Fry B, Maller J, Daly, MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21: 263-265.
40. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: Regional visualization of genome-wide association scan results. Bioinformatics. 2010;26: 2336-2337.
41. Bigonnesse F, Marois M, Maheux R, Akoum, A. Interleukin-1 receptor accessory protein is constitutively expressed in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 2001; 7: 333-339.
42. Seo H, Choi Y, Shim J, Ka H. Regulatory mechanism for expression of IL1B receptors in the uterine endometrium and effects of IL1B on prostaglandin synthetic enzymes during the implantation period in pigs. Biol Reprod. 2012;87: 31.
43. NewmanG, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol. 201425;382(1): 570-582.
44. Perrier S, Caldefie-Chezet F, Vasson MP. IL-1 family in breast cancer: Potential interplay with leptin and other adipocytokines. FEBS Lett. 2009;583: 259-265.
45. Jensen LE, Whitehead AS. The 3- untranslated region of the membrane- bound IL-1R accessory proteinmRNAconfers tissue-specific destabilization. J Immunol. 2004;173: 6248-6258.